147 related articles for article (PubMed ID: 11717804)
21. Azamacrocyclic metal complexes as CXCR4 antagonists.
Tanaka T; Narumi T; Ozaki T; Sohma A; Ohashi N; Hashimoto C; Itotani K; Nomura W; Murakami T; Yamamoto N; Tamamura H
ChemMedChem; 2011 May; 6(5):834-9. PubMed ID: 21312334
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E
Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
[TBL] [Abstract][Full Text] [Related]
23. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
24. NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II.
Mori M; Liu D; Kumar S; Huang Z
Biochem Biophys Res Commun; 2005 Sep; 335(3):651-8. PubMed ID: 16115468
[TBL] [Abstract][Full Text] [Related]
25. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
Thoma G; Streiff MB; Kovarik J; Glickman F; Wagner T; Beerli C; Zerwes HG
J Med Chem; 2008 Dec; 51(24):7915-20. PubMed ID: 19053768
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1.
Catalano JG; Gudmundsson KS; Svolto A; Boggs SD; Miller JF; Spaltenstein A; Thomson M; Wheelan P; Minick DJ; Phelps DP; Jenkinson S
Bioorg Med Chem Lett; 2010 Apr; 20(7):2186-90. PubMed ID: 20194023
[TBL] [Abstract][Full Text] [Related]
27. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
[TBL] [Abstract][Full Text] [Related]
28. Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.
Miller JF; Turner EM; Gudmundsson KS; Jenkinson S; Spaltenstein A; Thomson M; Wheelan P
Bioorg Med Chem Lett; 2010 Apr; 20(7):2125-8. PubMed ID: 20207537
[TBL] [Abstract][Full Text] [Related]
29. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
30. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
[TBL] [Abstract][Full Text] [Related]
31. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
34. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres.
Narumi T; Hayashi R; Tomita K; Kobayashi K; Tanahara N; Ohno H; Naito T; Kodama E; Matsuoka M; Oishi S; Fujii N
Org Biomol Chem; 2010 Feb; 8(3):616-21. PubMed ID: 20090978
[TBL] [Abstract][Full Text] [Related]
37. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.
Tamamura H; Sugioka M; Odagaki Y; Omagari A; Kan Y; Oishi S; Nakashima H; Yamamoto N; Peiper SC; Hamanaka N; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Feb; 11(3):359-62. PubMed ID: 11212110
[TBL] [Abstract][Full Text] [Related]
38. What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):408-10. PubMed ID: 16258879
[TBL] [Abstract][Full Text] [Related]
39. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor.
Våbenø J; Nikiforovich GV; Marshall GR
Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459
[TBL] [Abstract][Full Text] [Related]
40. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
Zhang H; Kang D; Huang B; Liu N; Zhao F; Zhan P; Liu X
Eur J Med Chem; 2016 May; 114():65-78. PubMed ID: 26974376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
